HK Stock Market Move | Everest Med (01952) previously surged over 5% in the afternoon. V-Shine's new drug application for listing has been approved by the National Medical Products Administration.

Everest Med (01952) rose by over 5% in the afternoon, and as of the time of writing, it has risen by 3.4%, reaching 40.18 Hong Kong dollars, with a turnover of 1.51 billion Hong Kong dollars. On the news front, on February 6th at noon, Everest Med announced that the National Medical Products Administration (NMPA) of China had approved the new drug application for Velsipity (arginine aspartate moxifloxacin tablets) for the treatment of moderate to severe active ulcerative colitis (UC) in adults who have had an inadequate response, no response, or are intolerant to traditional therapy or biologics. The company stated that they will actively prepare for the commercial launch of Velsipity and bring this treatment to domestic patients as soon as possible, while actively promoting its inclusion in the national medical insurance directory. The announcement pointed out that the approval of this new drug application is an important part of the company's 2030 development strategy, which clearly states that "BD cooperation + self-research" will drive commercialization to create deterministic value and research and development to create growth value. The company will continue to consolidate its advantages in core treatment areas, promote innovative drug research and development, and create a sustainable growth global innovative biopharmaceutical company.